• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

喉癌诊断后生存预测因素。

Factors predicting survival after diagnosis of laryngeal cancer.

机构信息

Institute of Public Health, University of Heidelberg, Germany.

出版信息

Oral Oncol. 2011 Dec;47(12):1154-8. doi: 10.1016/j.oraloncology.2011.08.003. Epub 2011 Aug 27.

DOI:10.1016/j.oraloncology.2011.08.003
PMID:21873105
Abstract

Survival in patients with laryngeal cancer has not increased remarkably within the last years. It is presumed that a variety of factors act jointly in predicting survival after diagnosis: tumour stage, tumour site, treatment approaches, age and comorbidities. The aim of this German clinical multi-centre study is to present results from multivariate analysis. A retrospective cohort study was conducted in four hospitals in South-West Germany. Incident cases with laryngeal squamous cell carcinoma were included for the years 1998 to 2004, resulting in a population sample of 594 patients. Multivariate regression analysis was performed using the Cox proportional hazards model. Patients were followed up for 64.1months on average. Overall 5-year survival was 66% (95% confidence interval (CI): 62-70%). The strongest risk factors in multivariate analysis were age at first diagnosis (hazard ratio (HR): 1.5; 95% CI: 1.5-1.7 per each additional 10years), tumour stage, and the development of recurrences (HR 3.1; 95% CI: 2.3-4.2) or second primary carcinomas (HR 2.1; 95% CI: 1.4-3.1). A somewhat weaker effect was shown for patients with comorbidities (using Charlson's comorbidity index). The choice of treatment did not strongly affect survival when adjusting for other factors, possibly because the optimal treatment approach was applied for the specific constitution and requirements of each patient. For future research it would be desirable to study the effect of treatment on quality of life in multivariate analysis as well as other modifiable risk factors as smoking and drinking reduction or cessation after diagnosis.

摘要

近年来,喉癌患者的生存率并没有显著提高。据推测,多种因素共同作用于诊断后的生存预测:肿瘤分期、肿瘤部位、治疗方法、年龄和合并症。这项德国临床多中心研究的目的是展示多变量分析的结果。在德国西南部的四家医院进行了一项回顾性队列研究。纳入了 1998 年至 2004 年患有喉鳞状细胞癌的发病病例,共纳入 594 例患者。使用 Cox 比例风险模型进行多变量回归分析。患者平均随访 64.1 个月。总 5 年生存率为 66%(95%置信区间:62-70%)。多变量分析中最强的危险因素是首次诊断时的年龄(风险比(HR):每增加 10 岁,HR:1.5;95%置信区间:1.5-1.7)、肿瘤分期以及复发(HR:3.1;95%置信区间:2.3-4.2)或第二原发癌(HR:2.1;95%置信区间:1.4-3.1)的发展。患有合并症的患者(使用 Charlson 合并症指数)的风险略低。在调整其他因素后,治疗方法的选择对生存的影响并不强烈,这可能是因为针对每个患者的具体情况和需求选择了最佳的治疗方法。在未来的研究中,理想情况下应在多变量分析中研究治疗对生活质量的影响以及其他可改变的危险因素,如吸烟和饮酒减少或诊断后戒烟。

相似文献

1
Factors predicting survival after diagnosis of laryngeal cancer.喉癌诊断后生存预测因素。
Oral Oncol. 2011 Dec;47(12):1154-8. doi: 10.1016/j.oraloncology.2011.08.003. Epub 2011 Aug 27.
2
Comparison of the Adult Comorbidity Evaluation 27 and the Charlson Comorbidity indices in patients with laryngeal squamous cell carcinoma.喉鳞状细胞癌患者中成人共病评估27指数与查尔森共病指数的比较。
J Laryngol Otol. 2012 May;126(5):516-24. doi: 10.1017/S0022215112000254. Epub 2012 Mar 26.
3
Comorbidity measurement in patients with laryngeal squamous cell carcinoma.喉鳞状细胞癌患者的共病测量
ORL J Otorhinolaryngol Relat Spec. 2007;69(3):146-52. doi: 10.1159/000099223. Epub 2007 Jan 30.
4
Comorbid predictors of poor response to chemoradiotherapy for laryngeal squamous cell carcinoma.喉鳞状细胞癌化放疗反应不良的合并症预测因素。
Laryngoscope. 2012 Mar;122(3):565-71. doi: 10.1002/lary.22489. Epub 2012 Jan 17.
5
Improved survival is associated with treatment at high-volume teaching facilities for patients with advanced stage laryngeal cancer.生存率的提高与晚期喉癌患者在大容量教学医院接受治疗有关。
Cancer. 2010 Oct 15;116(20):4744-52. doi: 10.1002/cncr.25364.
6
The impact of comorbidity on the survival of patients with laryngeal squamous cell carcinoma.合并症对喉鳞状细胞癌患者生存的影响。
Acta Otolaryngol. 2011 Aug;131(8):840-6. doi: 10.3109/00016489.2011.564651. Epub 2011 Apr 15.
7
[Results of definitive radiotherapy for squamous cell carcinomas of the larynx patients with subglottic extension].[声门下扩展型喉鳞状细胞癌患者的根治性放射治疗结果]
Cancer Radiother. 2014 Jan;18(1):1-6. doi: 10.1016/j.canrad.2013.06.047. Epub 2013 Dec 3.
8
Tissue microarray analysis reveals prognostic significance of COX-2 expression for local relapse in T1-2N0 larynx cancer treated with primary radiation therapy.组织微阵列分析揭示了COX-2表达对接受原发性放射治疗的T1-2N0喉癌局部复发的预后意义。
Laryngoscope. 2004 Nov;114(11):2001-8. doi: 10.1097/01.mlg.0000147936.67379.e7.
9
Surgical treatment and prognosis of thymic squamous cell carcinoma: a retrospective analysis of 105 cases.胸腺鳞状细胞癌的外科治疗和预后:105 例回顾性分析。
Ann Thorac Surg. 2013 Sep;96(3):1019-24. doi: 10.1016/j.athoracsur.2013.04.078. Epub 2013 Jul 16.
10
Supraglottic laryngeal cancer: analysis of treatment results.声门上型喉癌:治疗结果分析
Laryngoscope. 2005 Aug;115(8):1402-10. doi: 10.1097/01.MLG.0000166896.67924.B7.

引用本文的文献

1
A retrospective study of laryngeal squamous cell carcinoma and the significance of the PIK3CA mutation for survival.喉鳞状细胞癌的回顾性研究及PIK3CA突变对生存的意义。
Mol Clin Oncol. 2025 Jul 17;23(4):87. doi: 10.3892/mco.2025.2882. eCollection 2025 Oct.
2
Influential Factors on Survival in Laryngeal Cancer and Treatment Modalities Comparison.喉癌生存的影响因素及治疗方式比较
ORL J Otorhinolaryngol Relat Spec. 2025;87(1):27-38. doi: 10.1159/000543445. Epub 2025 Jan 14.
3
Risk of second primary cancer in patients with head and neck squamous cell carcinoma: a systemic review and meta-analysis.
头颈部鳞状细胞癌患者发生第二原发性癌症的风险:一项系统评价和荟萃分析。
Clin Oral Investig. 2023 Sep;27(9):4897-4910. doi: 10.1007/s00784-023-05066-3. Epub 2023 Aug 4.
4
Clinicopathological Characteristics, Treatment Patterns, and Outcomes in Patients with Laryngeal Cancer.喉癌患者的临床病理特征、治疗模式和结局。
Curr Oncol. 2023 Apr 20;30(4):4289-4300. doi: 10.3390/curroncol30040327.
5
p53 and PTEN expression evaluation with molecular evident recent criteria in laryngeal carcinoma.用分子学最新标准评估喉癌中的 p53 和 PTEN 表达。
Medicine (Baltimore). 2023 May 12;102(19):e33676. doi: 10.1097/MD.0000000000033676.
6
[Larynx preservation: recommendations for decision-making in T3 laryngeal cancer patients].[喉保留:T3期喉癌患者决策的建议]
HNO. 2022 Aug;70(8):581-587. doi: 10.1007/s00106-022-01177-7. Epub 2022 May 16.
7
Chemoradiotherapy but Not Radiotherapy Alone for Larynx Preservation in T3. Considerations from a German Observational Cohort Study.T3期喉癌保喉治疗采用放化疗而非单纯放疗:来自德国一项观察性队列研究的思考
Cancers (Basel). 2021 Jul 8;13(14):3435. doi: 10.3390/cancers13143435.
8
A Prospectively Validated Prognostic Model for Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck Based on Radiomics of Computed Tomography Images.基于计算机断层扫描图像放射组学的局部晚期头颈部鳞状细胞癌患者前瞻性验证预后模型
Cancers (Basel). 2021 Jun 29;13(13):3271. doi: 10.3390/cancers13133271.
9
Investigation of the affective factors on the survival rate of patients with laryngeal cancer using Cox proportional hazards and Lin -Ying's additive hazards models.使用Cox比例风险模型和林-英加法风险模型对影响喉癌患者生存率的情感因素进行调查。
Med J Islam Repub Iran. 2021 Feb 2;35:16. doi: 10.47176/mjiri.35.16. eCollection 2021.
10
Seeking Medical Assistance for Dysphonia Is Associated with an Improved Survival Rate in Laryngeal Cancer: Real-World Evidence.因声音嘶哑寻求医疗救助与喉癌生存率提高相关:真实世界证据
Diagnostics (Basel). 2021 Feb 7;11(2):255. doi: 10.3390/diagnostics11020255.